Inclusion Criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the pancreas

          2. Proven unresectability after multidisciplinary discussion involving radiologist and a
             surgeon

          3. Locally advanced (i.e.: no metastasis or suspicion of metastasis) and unresectable
             tumors: for example mesenteric or portal vein involvement, or > 180° encasement of the
             superior mesenteric artery, or celiac abutment (NCCN 2012 criteria)

          4. Measurable tumor lesions with longest diameter ≥ 20 mm using conventional techniques
             or ≥ 10 mm with spiral CT scan according RECIST 1.1

          5. WHO Performance status (PS) 0-1

          6. Age ≥18 years

          7. Patient with organ function as follows:

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L

               -  Hemoglobin ≥ 10 g/dL

               -  Platelets (PTL) ≥ 75 x 10⁹/L

               -  Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 2.5 x upper
                  limit of normal (ULN)

               -  Bilirubin ≤ 1.5 x ULN

               -  Creatinine ≤ 2 x ULN

               -  Albumin > 0.75 x lower limit of normal (LLN)

               -  Urea ≤ 2 x ULN

          8. Adequate vital functions

          9. Patient of child-bearing potential (for female patient: study entry after a menstrual
             period and a negative pregnancy test) must agree to use medically acceptable methods
             of contraception during the study and for 4 months after the last intake of study
             treatment for women and for 6 months after for men.

         10. Patient information and signed informed consent form

         11. Public or private health insurance coverage

         12. Uracilemia < 16 ng/ml

        Exclusion Criteria:

          1. Patient treated for a cancer other than pancreatic cancer within 5 years before
             enrolment, with the exception of basal cell carcinoma or in situ cervical cancer

          2. Patient with metastasis or with history of metastasis

          3. Patient with grade III/IV cardiac problems as defined by the New York Heart
             Association Criteria. (i.e. congestive heart failure, myocardial infarction within 6
             months before baseline)

          4. Major comorbidity, active infection (HIV or chronic hepatitis B or C) or uncontrolled
             diabetes that may preclude the delivery of the treatment

          5. Pre-existing neuropathy (Grade ≥ 2), Gilbert's disease or genotype UGT1A1 * 28 / * 28

          6. Pregnant woman

          7. Fructose intolerance

          8. Patients currently treated by warfarin

          9. Persons deprived of liberty or under guardianship

         10. Psychological condition, family-, sociological- or geographical situation potentially
             hampering compliance with the study protocol and the follow-up schedule